• Company
• Marketability of homegrown drugs being tested in the US
• by Chon, Seung-Hyun Dec 20, 2023 05:41am

• Policy
• Bill pending on substituting dispositions for illegal rebate
• by Lee, Jeong-Hwan Dec 20, 2023 05:40am

• Opinion
• [Reporter's view] Bothered by the PE exemption system
• by Eo, Yun-Ho Dec 20, 2023 05:40am

• Policy
• Forxiga generics continue being released in the Korean mkt
• by Lee, Tak-Sun Dec 20, 2023 05:40am

• InterView
• Targeted cardiomyopathy drug, Camzyos effective in Asians
• by Son, Hyung-Min Dec 19, 2023 11:19am

• Company
• LG Chem joins in the 3-way race in Humira biosimilar mkt
• by Chon, Seung-Hyun Dec 19, 2023 05:54am

• Company
• 2 new JAK inhibitors secure expanded reimb
• by Son, Hyung-Min Dec 19, 2023 05:54am

• Company
• Baxter-JW-HK Inno.N-Kabi introduce 4th gen 3 chamber TPNs
• by Nho, Byung Chul Dec 19, 2023 05:53am

• Policy
• New drugs Zeposia, Koselugo, Trimbow are reimbursed
• by Lee, Tak-Sun Dec 19, 2023 05:53am

• Company
• Who will take over the Forxiga market worth 50 bil?
• by Chon, Seung-Hyun Dec 18, 2023 05:31am